Zobrazeno 1 - 6
of 6
pro vyhledávání: '"F. J. Martínez-Cerezo"'
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 102, Iss 11, Pp 674-675 (2010)
Externí odkaz:
https://doaj.org/article/040f2635c7a94646980328c45afaa208
Publikováno v:
Revista Española de Enfermedades Digestivas v.102 n.11 2010
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Europe PubMed Central
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0cc013c1fdaf95cac7bf0f4037b347
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001100016
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001100016
Publikováno v:
Gastroenterologia y hepatologia. 27(7)
We report a patient at high surgical risk with an early gastric adenocarcinoma. Due to the size of the tumor, endoscopic mucosal resection alone was not feasible and consequently a combination of endoscopic resection with polypectomy snare and argon
Publikováno v:
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 88(10)
Autor:
F J, Martínez Cerezo
Publikováno v:
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 86(3)
Hepatocellular carcinoma is the most frequent hepatic primary neoplasm. Its geographic distribution is inhomogeneous, with high, medium and low zones of incidence. The role of etiologic factors such as aflatoxin exposure. Hepatitis B virus, hepatitis
Autor:
F J, Martínez Cerezo, M, Puig, A, Martínez Nogueras, A, Tomás, J, Pamplona, C, Guarner, J, Balanzó, J, Enríquez, F, Vilardell
Publikováno v:
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 84(5)
The size and the treatment of 135 hepatocellular carcinomas (HCC) has been analyzed, comparing patients diagnosed by a US screening program (group 1) and these diagnosed outside this program (group 2) to determine whether US screening on patients wit